Abstract
Common mechanisms contribute to the simultaneousdevelopment and progression of CVD and CKD. Hence,similar therapies could be positive to improve renal andCV prognosis. However, improvement in our under-standing of why a significant proportion of patients withCKD progress to end-stage renal disease (ESRD) and/ordie from CVD, whereas others remain stable, is urgentlyrequired. Identification of individualized determinantsof CKD progression and or premature CVD will lead tonovel, innovative nephroprotective and/or cardiopro-tective pharmacologic treatment in these high-riskpatients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of clinical hypertension (Greenwich, Conn.)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
